Toll Free: 1-888-928-9744

Irritable Bowel Syndrome - Pipeline Review, H1 2016

Published: May 18, 2016 | Pages: 144 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Irritable Bowel Syndrome - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Irritable Bowel Syndrome - Pipeline Review, H1 2016', provides an overview of the Irritable Bowel Syndrome pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Irritable Bowel Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Irritable Bowel Syndrome and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Irritable Bowel Syndrome
- The report reviews pipeline therapeutics for Irritable Bowel Syndrome by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Irritable Bowel Syndrome therapeutics and enlists all their major and minor projects
- The report assesses Irritable Bowel Syndrome therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Irritable Bowel Syndrome

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Irritable Bowel Syndrome
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Irritable Bowel Syndrome pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Irritable Bowel Syndrome Overview 10 Therapeutics Development 11 Pipeline Products for Irritable Bowel Syndrome - Overview 11 Irritable Bowel Syndrome - Therapeutics under Development by Companies 12 Irritable Bowel Syndrome - Pipeline Products Glance 14 Late Stage Products 14 Clinical Stage Products 15 Early Stage Products 16 Irritable Bowel Syndrome - Products under Development by Companies 17 Irritable Bowel Syndrome - Companies Involved in Therapeutics Development 19 4D Pharma Plc 19 A. Menarini Industrie Farmaceutiche Riunite Srl 20 Alfa Wassermann S.p.A 21 Allergan Plc 22 Ardelyx, Inc. 23 Astellas Pharma Inc. 24 CJ HealthCare Corp. 25 Enterome Bioscience SA 26 Innovate Biopharmaceuticals, Inc. 27 Ironwood Pharmaceuticals, Inc. 28 Kissei Pharmaceutical Co., Ltd. 29 Lexicon Pharmaceuticals, Inc. 30 Ono Pharmaceutical Co., Ltd. 31 Pfizer Inc. 32 Protagonist Therapeutics Inc. 33 RaQualia Pharma Inc. 34 RedHill Biopharma Ltd. 35 SK Biopharmaceuticals Co., Ltd. 36 Sumitomo Dainippon Pharma Co., Ltd. 37 Synergy Pharmaceuticals, Inc. 38 Synthetic Biologics, Inc. 39 Takeda Pharmaceutical Company Limited 40 Irritable Bowel Syndrome - Therapeutics Assessment 41 Assessment by Monotherapy Products 41 Assessment by Target 42 Assessment by Mechanism of Action 44 Assessment by Route of Administration 46 Assessment by Molecule Type 48 Drug Profiles 50 ASP-1017 - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 ASP-7147 - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 bedoradrine sulfate - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 Blautix - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 CJ-14199 - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 crofelemer DR - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 DA-6886 - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 DSP-6952 - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 EB-120 - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 eluxadoline - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 ibodutant - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 larazotide acetate - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 linaclotide - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 lovastatin - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 LX-1033 - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 ondansetron hydrochloride CR - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 ONO-2952 - Drug Profile 74 Product Description 74 Mechanism of Action 74 R&D Progress 74 PBF-677 - Drug Profile 76 Product Description 76 Mechanism of Action 76 R&D Progress 76 plecanatide - Drug Profile 77 Product Description 77 Mechanism of Action 77 R&D Progress 77 pregabalin - Drug Profile 78 Product Description 78 Mechanism of Action 78 R&D Progress 78 relenopride hydrochloride - Drug Profile 81 Product Description 81 Mechanism of Action 81 R&D Progress 81 rifaximin - Drug Profile 82 Product Description 82 Mechanism of Action 82 R&D Progress 82 RQ-00202730 - Drug Profile 85 Product Description 85 Mechanism of Action 85 R&D Progress 85 RQ-00310941 - Drug Profile 86 Product Description 86 Mechanism of Action 86 R&D Progress 86 Small Molecules to Inhibit 5-HT2B and 5-HT7 Receptors for IBS and Migraine - Drug Profile 87 Product Description 87 Mechanism of Action 87 R&D Progress 87 solabegron hydrochloride - Drug Profile 88 Product Description 88 Mechanism of Action 88 R&D Progress 88 Synthetic Peptide for Irritable Bowel Syndrome with Diarrhea - Drug Profile 90 Product Description 90 Mechanism of Action 90 R&D Progress 90 TAK-480 - Drug Profile 91 Product Description 91 Mechanism of Action 91 R&D Progress 91 tenapanor hydrochloride - Drug Profile 92 Product Description 92 Mechanism of Action 92 R&D Progress 92 Irritable Bowel Syndrome - Recent Pipeline Updates 94 Irritable Bowel Syndrome - Dormant Projects 130 Irritable Bowel Syndrome - Discontinued Products 135 Irritable Bowel Syndrome - Product Development Milestones 136 Featured News & Press Releases 136 Apr 11, 2016: RedHill Biopharma Initiates Phase II Study of BEKINDA for Irritable Bowel Syndrome 136 Mar 07, 2016: Napo and Salix Settle Litigation 137 Feb 29, 2016: Video Alert: Updated 2016 Direct-to-Consumer Awareness Campaign Available for LINZESS (linaclotide) 137 Feb 26, 2016: Clinical Update On Blautix For The Treatment Of Irritable Bowel Syndrome : 4D pharma 138 Feb 24, 2016: Ironwood Pharmaceuticals Announces Filing by Astellas of New Drug Application in Japan with Linaclotide for the Treatment of Adults with IBS-C 138 Feb 17, 2016: Synthetic Biologics Announces the Allowance of Key U.S. Patent Covering SYN-010 intended for the Novel Treatment of Irritable Bowel Syndrome with Constipation 139 Feb 11, 2016: RedHill Biopharma Announces Successful PK Study with BEKINDA 12 mg and Submission to FDA of IBS-D Phase II Study Protocol 139 Jan 21, 2016: VIBERZI (eluxadoline) Phase III Trial Results Published in The New England Journal of Medicine 140 Jan 19, 2016: Clinical Update on Blautix, a novel treatment for Irritable Bowel Syndrome 141 Jan 19, 2016: Synthetic Biologics Reports Positive Topline Data from Second Phase 2 Clinical Trial of SYN-010 in Patients with Irritable Bowel Syndrome with Constipation (IBS-C) 142 Appendix 143 Methodology 143 Coverage 143 Secondary Research 143 Primary Research 143 Expert Panel Validation 143 Contact Us 143 Disclaimer 144
List of Tables
Number of Products under Development for Irritable Bowel Syndrome, H1 2016 11 Number of Products under Development by Companies, H1 2016 12 Number of Products under Development by Companies, H1 2016 (Contd..1) 13 Comparative Analysis by Late Stage Development, H1 2016 14 Comparative Analysis by Clinical Stage Development, H1 2016 15 Comparative Analysis by Early Stage Development, H1 2016 16 Products under Development by Companies, H1 2016 17 Products under Development by Companies, H1 2016 (Contd..1) 18 Irritable Bowel Syndrome - Pipeline by 4D Pharma Plc, H1 2016 19 Irritable Bowel Syndrome - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2016 20 Irritable Bowel Syndrome - Pipeline by Alfa Wassermann S.p.A, H1 2016 21 Irritable Bowel Syndrome - Pipeline by Allergan Plc, H1 2016 22 Irritable Bowel Syndrome - Pipeline by Ardelyx, Inc., H1 2016 23 Irritable Bowel Syndrome - Pipeline by Astellas Pharma Inc., H1 2016 24 Irritable Bowel Syndrome - Pipeline by CJ HealthCare Corp., H1 2016 25 Irritable Bowel Syndrome - Pipeline by Enterome Bioscience SA, H1 2016 26 Irritable Bowel Syndrome - Pipeline by Innovate Biopharmaceuticals, Inc., H1 2016 27 Irritable Bowel Syndrome - Pipeline by Ironwood Pharmaceuticals, Inc., H1 2016 28 Irritable Bowel Syndrome - Pipeline by Kissei Pharmaceutical Co., Ltd., H1 2016 29 Irritable Bowel Syndrome - Pipeline by Lexicon Pharmaceuticals, Inc., H1 2016 30 Irritable Bowel Syndrome - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016 31 Irritable Bowel Syndrome - Pipeline by Pfizer Inc., H1 2016 32 Irritable Bowel Syndrome - Pipeline by Protagonist Therapeutics Inc., H1 2016 33 Irritable Bowel Syndrome - Pipeline by RaQualia Pharma Inc., H1 2016 34 Irritable Bowel Syndrome - Pipeline by RedHill Biopharma Ltd., H1 2016 35 Irritable Bowel Syndrome - Pipeline by SK Biopharmaceuticals Co., Ltd., H1 2016 36 Irritable Bowel Syndrome - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2016 37 Irritable Bowel Syndrome - Pipeline by Synergy Pharmaceuticals, Inc., H1 2016 38 Irritable Bowel Syndrome - Pipeline by Synthetic Biologics, Inc., H1 2016 39 Irritable Bowel Syndrome - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 40 Assessment by Monotherapy Products, H1 2016 41 Number of Products by Stage and Target, H1 2016 43 Number of Products by Stage and Mechanism of Action, H1 2016 45 Number of Products by Stage and Route of Administration, H1 2016 47 Number of Products by Stage and Molecule Type, H1 2016 49 Irritable Bowel Syndrome Therapeutics - Recent Pipeline Updates, H1 2016 94 Irritable Bowel Syndrome - Dormant Projects, H1 2016 130 Irritable Bowel Syndrome - Dormant Projects (Contd..1), H1 2016 131 Irritable Bowel Syndrome - Dormant Projects (Contd..2), H1 2016 132 Irritable Bowel Syndrome - Dormant Projects (Contd..3), H1 2016 133 Irritable Bowel Syndrome - Dormant Projects (Contd..4), H1 2016 134 Irritable Bowel Syndrome - Discontinued Products, H1 2016 135


List of Figures
Number of Products under Development for Irritable Bowel Syndrome, H1 2016 11 Number of Products under Development by Companies, H1 2016 12 Comparative Analysis by Late Stage Development, H1 2016 14 Comparative Analysis by Clinical Stage Development, H1 2016 15 Comparative Analysis by Early Stage Products, H1 2016 16 Assessment by Monotherapy Products, H1 2016 41 Number of Products by Top 10 Targets, H1 2016 42 Number of Products by Stage and Top 10 Targets, H1 2016 42 Number of Products by Top 10 Mechanism of Actions, H1 2016 44 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 44 Number of Products by Routes of Administration, H1 2016 46 Number of Products by Stage and Routes of Administration, H1 2016 46 Number of Products by Molecule Types, H1 2016 48 Number of Products by Stage and Molecule Types, H1 2016 48

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

North America air conditioner market size is expected to be valued at USD 52,560.7 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing usage of energy efficient air conditioners owing to declining energy consumption rat

Read More...

Global data center UPS market size is estimated to reach USD 5.7 billion by 2020, as per a new research report by Radiant Insights, Inc. Declining tolerance levels pertaining to data loss along with amplifying acceptance of cloud computing is likely

Read More...

Global engineering service outsourcing market size is likely to be valued at USD 415.7 billion by 2020, as per a new research report by Radiant Insights, Inc. Rapid alignment of OEMs accompanied by increasing focus on efficient performance and reliab

Read More...

Global Biocides market size is likely to be valued at USD 11.9 billion by 2022; as per a new research report by Radiant Insights, Inc. Growth in water treatment process units particularly in China, Japan and India is likely to drive demand. Increasin

Read More...

Global air traffic control equipment market is projected to reach USD 4.2 billion by 2020, as per a new research report by Radiant Insights, Inc. Mounting price sensitivity among customers with introduction of low fare airlines is expected to drive t

Read More...
Choose License Type
Single User - US $2000
Multi User - US $4000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify